METAL CONJUGATED MONOCLONAL ANTIBODIES FOR TUMOR DIAGNOSIS AND THERAPY

用于肿瘤诊断和治疗的金属偶联单克隆抗体

• 批准号: 4692108
• 负责人: O A GANSOW
• 金额: --
• 依托单位: DIVISION OF CANCER TREATMENT
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/4692108
• 关键词: antitumor antibody; chelating agents; disease /disorder model; drug design /synthesis /production; immunoconjugates; monoclonal antibody; mouse leukemia; neoplasm /cancer immunodiagnosis; neoplasm /cancer radiodiagnosis; neoplasm /cancer radionuclide therapy; neoplasm /cancer transplantation; radiopharmacology; viral leukemia

Tumor-associated monoclonal antibodies are potential therapeutic agents as selective carriers of cytotoxic agents to malignant cells. We are testing this hypothesis in serveral animal model systems: one is a tumor virus leukemia of mice, another is human tumor xenographs in nude athymic mice. The various cytocidal agents being employed are radioisotopes. Their relative therapeutic efficacy when conjugated to antibodies is being assayed and compared that of monoclonal antibodies alone. The isotopes to be employed include the highly tumoricidal alpha emitting parent radioisotopes Pb-212 or Bi-212. The syntheses of different chelates and radiochemical separations required for these objectives are being devised and reduced to clinical practice. Results from isotopic therapy are being compared with those obtained by use of antibody conjugated toxins or drugs with respect to tumor growth, regression or cure. These studies will provide for human medicine a basis for design or rational therapy of malignancies by selectively targeting cytocidal agents to tumors as well as metastases. New chelates for use in this project have been synthesized and are in testing, and have thus far proven useful for Radiobiology studies of cell killing with alpha particle labeled antibody.

肿瘤相关的单克隆抗体是潜在的治疗剂 细胞毒性剂对恶性细胞的选择性载体。 我们正在测试 服务器动物模型系统中的这一假设：一种是肿瘤病毒 小鼠的白血病，另一个是裸露小鼠中的人类肿瘤特征。 所采用的各种细胞固定剂是放射性同位素。 他们的 当与抗体结合时，相对治疗功效正在 分析并比较单独的单克隆抗体。 同位素 被使用包括高度肿瘤的α发出父母 放射性病PB-212或BI-212。 不同螯合物的合成和 这些目标所需的放射性分离正在设计 并减少到临床实践。 同位素治疗的结果正在 与使用抗体结合的毒素或药物获得的抗体相比 关于肿瘤生长，回归或治愈。 这些研究将为人类医学提供设计的基础或 通过选择性靶向细胞固定剂，对恶性肿瘤的合理治疗 到肿瘤以及转移酶。 在此项目中使用的新螯合物已合成并已在 测试，迄今已证明对细胞的放射生物学研究有用 用标记为抗体的α颗粒杀死。